In Conversation

The 2030 goals are not the last mile, and the lack of political will to work towards achieving them is a big concern

What gives me hope is the incredible progress in the scientific tools at our disposal and our understanding of what we are after

We are in the business of excellent clinical evidence. EMA wants to partner with stakeholders, including those from industry, to drive up the quality of evidence…

We need to engage more, explain the system, and clarify the steps that we are taking

What does AI really mean? How can we make the equipment safe? The solution will be to start with low hanging fruit where risk is low…

Our motto is simple yet ambitious—everything for everyone, everywhere. I wish for peace, health, and reflection on our shared humanity in these challenging times

We aim to positively surprise our customers and partners with innovative approaches

It's important not to forget the significant contributions made by the pharmaceutical industry during the pandemic. The promises and commitments made by industry players and governments…

While generics continue to be a core focus, there has been a strategic shift towards emphasising innovation

Leveraging this resource [the Systeme National des Donnees de Sante (SNDS)], we conduct numerous real-world studies, positioning France among the leaders in real-world evidence generation within…

[We must] avoid placing AI at the centre and then working backwards to find a problem. Instead, we should take a problem-centric approach, identifying real-world challenges…

The funding landscape for science in Portugal is facing challenges that stem from a decrease in overall investment and shifting priorities. Despite the evident role of…

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here